Shavit News
2011
- Elbit Vision Systems Ltd. launched its innovative technology during ITMA exhibition, receiving over $1 M orders (PRNewswire)
October 17, 2011
- Kamada: Investment opportunity analysis and buy recommendation (Globes)
September 25, 2011
- Kamada Investors Presentation (TASE Filing)
September 1, 2011
- Kamada begins manufacturing of snake venom antiserums for Israeli Ministry of Health (Globes)
August 8, 2011
- Kamada obtains FDA orphan drug status for diabetes treatment (Globes)
August 3, 2011
- Kamada signs rabies vaccine partnership deal in US (MENA.FN)
July 20, 2011
- Kamada CEO: “We are heading for another strategic partnership agreement” (Globes)
June 6, 2011
- Excellent annual report and projections for Kamada: expect 50% increase in revenue in 2011 (Globes)
March 30, 2011
- Sam Cohen and Yaron Menashe turn-around Elbit Vision Systems (TheMarker)
March 23, 2011
- Positive interim results for Kamada’s clinical trial using inhaled AAT for treatment of Emphysema (TheMarker)
February 14, 2011
- Kamada enters the diabetes market: a new indication for its flagship drug Glassia (TheMarker)
February 9, 2011
- Clal Finance raises Kamada’s target share price by 50% following Baxter agreement (TheMarker)
January 23, 2011
Back to Top
2010
- Kamada expects $35m total revenue in 2010 (Globes)
November 29, 2010
- Kamada near strategic deal to sell its rabies vaccine in US (Globes)
November 11, 2010
- Gary Leibler, Managing Partner of Shavit Capital, Comments on Convertible Debt vs. Equity Investments (Globes)
October 26, 2010
- Baxter Launches GLASSIATM in the U.S. (Baxter PR)
October 25, 2010
- Kamada awarded US patent for the manufacturing process of its AAT drug (Globes)
October 25, 2010
- Russia OK's Kamada's rabies vaccine (Haaretz)
September 15, 2010
- Kamada Baxter Announces Manufacturing, Supply and Distribution Agreement with Kamada for GLASSIA (Baxter PR)
August 24, 2010
- Kamada signs exclusive distribution agreement with Baxter for its AAT drug (TheMarker)
August 24, 2010
- Summary of the Kamada – Baxter Strategic Agreement (Presentation to Investors)
August 24, 2010
- Kamada Wins FDA Approval for Glassia - a new liquid, ready-to-use treatment for Alpha-1 Antitrypsin Deficiency (FierceBiotech)
July 6, 2010
- Kamada wins FDA approval for the first biological drug by an Israeli company (TheMarker)
July 4, 2010
- EVS Announces partial forgiveness and restructuring of $7m bank debt and sale of Scanmaster systems (Company PR)
June 1, 2010
- The BioTech index on TASE is launched: The 3 “Biggest” are Given , Kamada and Compugen (Globes)
February 25, 2010
- Kamada enrolls the first patient for its phase II-III clinical trial of Aerosolized AAT (TheMarker)
January 26, 2010
Back to Top
2009
- Kamada raised 95.6 million NIS in convertible bonds (Globes)
October 19, 2009
- Kamada to raise135 million NIS via convertible bonds and a rights offering (Globes)
October 15, 2009
- Kamada starts the final phase of clinical trials with Aerosolized AAT in Europe (Globes)
October 11, 2009
- Controlling stakeholder at Kamada: “Our strategy is to go all the way” (TheMarker)
October 10, 2009
- Kamada signs a $15m distribution agreement of Intravenous AAT in the US (TheMarker)
August 27, 2009
- Kamada takes another step towards a $550m potential market (TheMarker)
August 5, 2009
- Kamada Investor Presentation June 2009 (Kamada Filing)
June 9, 2009
- Kamada successfully completed Phase II clinical trials with its Aerosolized AAT for Bronchiectasis (Globes)
June 8, 2009
- Kamada signs agreements for a 39.45 million NIS investment in the comapny (Globes)
May 18, 2009
- Meitav to invest 6 million NIS in Kamada (Bizportal)
May 10, 2009
- Kamada to develop snake venom antiserum for the Israeli Ministry of Health for 20 million NIS (Globes)
March 9, 2009
- Kamada announces $7 million private allocation of common stock (BusinessWire)
February 25, 2009
- Kamada raises $7m from existing and new shareholders (Globes)
February 24, 2009
- Kamada raises capital: $7m to be invested by existing shareholders and UDT Med Holdings (Bizportal)
February 24, 2009
- Elbit Vision System wins orders from two leading US-Based aerospace manufacturers and reports cost reduction measures (EVS PR)
January 6, 2009
Back to Top
2008
- Kamada Investor Presentation December 2008 (Kamada Filing)
December 17, 2008
- Elbit Vision System wins orders from two leading Chinese manufacturers (EVS PR)
December 8, 2008
- Kamada announces Q3 2008 Financial Reports (Kamada Filing)
November 30, 2008
- Elbit Vision Systems announces record revenue for the third quarter of 2008 (EVS Filing)
November 24, 2008
- Kamada successfully completed Phase III clinical trial with Intravenous AAT for hereditary AAT deficiency (TheMarker)
October 26, 2008
- Kamada successfully completed Phase II clinical trials with Aerosolized AAT for Cystic Fibrosis (TheMarker)
October 15, 2008
- Kamada announces Q2 2008 Financial Reports (Kamada Filing)
August 21, 2008
- Elbit Vision Systems announces record revenue for the second quarter of 2008 (EVS Filing)
August 11, 2008
- Meitav: Kamada is the most ‘mature’ biopharmaceutical company on the Tel-Aviv Stock Exchange (TheMarker)
July 9, 2008
- I.B.I.: ‘Buy’ recommendation for Kamada at 85% premium to market price (TheMarker)
July 1, 2008
- Kamada Announces Successful Phase II Interim Results for its Aerosolized AAT (TheMarker)
June 4, 2008
- Kamada announces Q1 2008 Financial Reports (Kamada Filing)
May 29, 2008
- Elbit Vision Systems opens 2008 with a 20% growth in revenue (TheMarker)
May 22, 2008
- Elbit Vision Systems announces record revenue for the first quarter of 2008 (EVS Filing)
May 22, 2008
- Kamada announces the closing of Shavit Capital Fund deal (Kamada Filing)
April 30, 2008
- Bioville to join Shavit Capital Fund and co-invest $1m of the $4m investment in Kamada (Kamada Filing)
April 14, 2008
- Elbit Vision Systems Wins $1.3m in Orders For its Surface Inspection Products (EVS PR)
April 14, 2008
- Kamada was Granted New Orphan Drug Designation by the FDA, for its Aerosolized AAT for the treatment of Bronchiectasis (TheMarker)
April 9, 2008
- An additional, potential indication to Kamada's AAT - AAT proved efficient in treating Type-1 Diabetes in mice (BBC News)
April 7, 2008
- Elbit Vision Systems wins Orders from the Leading Aerospace Manufacturers and their Subcontractors (EVS PR)
April 3, 2008
- Kamada Announces that it had Successfully Met the Primary Endpoint in its US Phase III Clinical Trial with Intravenous AAT (Kamada PR)
April 2, 2008
- Kamada announces 2007 Financial Reports (Kamada Filing)
March 30, 2008
- Kamada Announces Advancement in its Phase II Trial with Aerosolized AAT to treat CF: First Group of Patients Completes Treatment (Kamada PR)
March 19, 2008
- Kamada Signs a $4m Private Equity Investment Agreement with Shavit Capital Fund (Kamada PR)
March 5, 2008
- Shavit Capital Fund to invest $4m in Kamada (Yediot)
March 5, 2008
- Kamada raises $4m from Private Investment Companies (TheMarker)
March 5, 2008
- Elbit Vision Systems announces record fourth quarter and full year 2007 results (EVS Filing)
February 19, 2008
Back to Top
2007
